CLINICAL TRIALS PROFILE FOR SIPONIMOD

All Clinical Trials for siponimod

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01185821 ↗	Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis	Completed	Novartis Pharmaceuticals	Phase 2	2010-08-30	This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg for approximately a further 3 years. It will provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient population
NCT01665144 ↗	Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)	Active, not recruiting	Novartis Pharmaceuticals	Phase 3	2012-12-20	Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).
NCT02029274 ↗	Safety and Efficacy of BAF312 in Dermatomyositis	Terminated	Novartis Pharmaceuticals	Phase 2	2013-08-25	This study investigated the dose response relationship for the efficacy and safety of BAF312 compared to placebo in active DM patients over a treatment period of 6+6 months and to determine the minimum dose required for a maximal clinical effect. The study was composed of 2 periods: a double-blind period 1 with BAF312 administered at different daily doses (0.5, 2, 10 mg and placebo) and a fixed-dose Period 2 in which BAF312 was administered at the dose of 2 mg daily .
NCT03338998 ↗	Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).	Completed	Novartis Pharmaceuticals	Phase 2	2017-12-24	This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)
NCT03498131 ↗	Melatonin in Patients With Multiple Sclerosis (MS).	Active, not recruiting	Providence Health & Services	Early Phase 1	2018-05-09	To date, there are no published data on the role of melatonin supplementation or the appropriate dose for patients with multiple sclerosis. Because of the potential benefits of melatonin, this pilot study will be an exploratory investigation to evaluate the effect of supplementing melatonin in subjects with multiple sclerosis who are taking an oral disease modifying therapy (DMT) for 6 months or longer. It is our intent that the results of this study will support the rationale and be a prelude to a larger trial which can focus on clinical efficacy of melatonin therapy outcomes.
NCT03623243 ↗	Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.	Recruiting	Novartis Pharmaceuticals	Phase 3	2019-02-14	To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
NCT04792567 ↗	Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)	Recruiting	Novartis Pharmaceuticals	Phase 4	2021-04-19	The purpose of this study is to understand whether participants can mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break.

Clinical Trial Conditions for siponimod

Condition Name

Condition Name for siponimod
Intervention	Trials
Relapsing Remitting Multiple Sclerosis	2
Secondary Progressive Multiple Sclerosis	2
Autoimmune Diseases of the Nervous System	1
Cognitive Impairment, Mild	1

Condition MeSH

Condition MeSH for siponimod
Intervention	Trials
Sclerosis	7
Multiple Sclerosis	7
Multiple Sclerosis, Chronic Progressive	3
Neoplasm Metastasis	3

Clinical Trial Locations for siponimod

Trials by Country

Trials by Country for siponimod
Location	Trials
United States	79
Spain	12
Japan	12
Italy	8
Canada	8

Trials by US State

Trials by US State for siponimod
Location	Trials
Florida	5
Ohio	4
Oregon	4
California	4
Arizona	4

Clinical Trial Progress for siponimod

Clinical Trial Phase

Clinical Trial Phase for siponimod
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	2
Phase 3	3

Clinical Trial Status

Clinical Trial Status for siponimod
Clinical Trial Phase	Trials
Recruiting	4
Active, not recruiting	2
Completed	2

Clinical Trial Sponsors for siponimod

Sponsor Name

Sponsor Name for siponimod
Sponsor	Trials
Novartis Pharmaceuticals	7
Providence Health & Services	1
Robert Zivadinov, MD, PhD	1

Sponsor Type

Sponsor Type for siponimod
Sponsor	Trials
Industry	9
Other	5
NIH	1

Siponimod Clinical Trials Update, Market Analysis, and Revenue Projection: Phase Status, Competitive Landscape, and Exclusivity Timeline

Last updated: July 27, 2026

Siponimod is an S1P receptor modulator in development for multiple sclerosis, with a public clinical footprint dominated by the pivotal phase program (SPARTAN: secondary progressive MS; and related studies in relapsing forms) and ongoing efforts to establish long-term efficacy and safety. Market upside depends on (1) whether siponimod expands labeling beyond the target phenotype supported by pivotal data, (2) uptake vs existing S1P competitors (notably fingolimod derivatives and other S1P modulators), and (3) timing of launch relative to patent and exclusivity expirations for comparators.

No complete, citation-ready package can be produced from the information available in this session, because the required dataset (current trial status and design, endpoints, enrollment/termination dates, FDA/EMA status, and sales and consensus forecasts) is not provided.

What clinical trials are ongoing for siponimod (SPMS and relapsing MS) and what are the latest results?

Featured snippet answer: A credible “latest results” update requires current trial registry outcomes (ClinicalTrials.gov and EUCTR), the trial status text (recruiting/active/not recruiting/completed), and the most recent posted results dates for each relevant study.

Which siponimod trials matter most for regulatory approval

H2 intent mapping for user search:

• “ongoing clinical trials”
• “latest results”
• “SPARTAN”
• “secondary progressive multiple sclerosis”
• “phase 3”
• “safety and efficacy”
• “biomarkers and MRI endpoints”

SPARTAN and secondary progressive MS: what endpoints typically support approval

Typical MS development logic for S1P modulators centers on:

• disability progression endpoints (3-month or 6-month confirmed)
• MRI lesion burden and brain volume
• relapse outcomes where applicable (if relapsing phenotypes are targeted)
• safety for immune suppression risk (infection rates, macular edema, bradycardia, lymphopenia)

How does siponimod compare with other S1P receptor modulators in multiple sclerosis (market positioning and efficacy)?

Featured snippet answer: Market positioning for siponimod depends on comparative performance versus the existing S1P class on disability progression, MRI activity, and safety tolerability, plus practical differentiators such as dosing, discontinuation strategy, and monitoring burden.

Key comparators for economic modeling

Common S1P MS comparators that compete for the same patient pools include:

• fingolimod (and derivatives)
• siponimod’s class-adjacent oral agents
• other disease-modifying therapies (DMTs) used in SPMS and relapsing MS

Where siponimod’s differentiation would affect forecast adoption

Economic adoption is most sensitive to:

• label scope (which MS subtypes get approved)
• effect size on confirmed disability progression
• safety profile that reduces switching costs and monitoring
• payer positioning (step edits, prior authorization, and step therapy)

What is the current FDA and EMA regulatory status of siponimod (approval timeline and submissions)?

Featured snippet answer: A reliable regulatory status update must include whether siponimod has an NDA/MAA, submission dates, major milestones (acceptance, filing, briefing packages), and any FDA/CHMP questions.

What regulatory events typically move siponimod from “development” to “market”

For revenue projection, the critical gating events are:

• submission acceptance (FDA “filing” vs “complete response”)
• label negotiations (endpoints, populations, warnings)
• postmarketing commitments
• risk evaluation and mitigation strategy requirements

When does siponimod lose exclusivity (patent and regulatory exclusivity timeline)?

Featured snippet answer: Exclusivity timelines require the full patent estate and any regulatory exclusivities (US patent term adjustments, SPCs in the EU, and potential data exclusivity periods). This session contains no patent list or jurisdictional filing details for siponimod.

What “lose exclusivity” means in practice for market entry

For generics:

• patent expiration and any listed Orange Book patents (US)
• Hatch-Waxman exclusivities if applicable
• market exclusivity in the EU through data protection and SPC periods

What patents protect siponimod (active ingredient, formulations, and method-of-use claims)?

Featured snippet answer: A defensible “how strong is the patent estate” view requires:

• publication numbers and claims scope
• assignees
• jurisdictional coverage (US, EP, WO)
• formulation vs method-of-use split

How patent scope affects generic and biosimilar risk

For small molecules like siponimod, generic risk is driven by:

• composition-of-matter coverage
• specific crystalline forms and salt forms
• formulation IP (if meaningful)
• method-of-use claims tied to approved indications

Are there any Paragraph IV filings or ANDA challenges for siponimod?

Featured snippet answer: A Paragraph IV risk screen requires Orange Book listings and any litigation dockets or FDA acceptance of ANDAs. No Orange Book record list or litigation docket is provided in this session.

What to model if an ANDA is filed

Revenue exposure is driven by:

• earliest generic approval date
• 180-day exclusivity triggers
• settlement terms that delay entry
• patent carve-outs in any settlement

What is the siponimod market opportunity (addressable population and uptake drivers)?

Featured snippet answer: A market model for siponimod must quantify:

• prevalent MS patient counts by phenotype (SPMS and relapsing)
• share treated with oral DMTs
• switching and persistence assumptions driven by efficacy and safety
• competitive penetration by the S1P class and higher-efficacy agents

Addressable patient pool logic for revenue modeling

For siponimod, forecastable penetration depends on:

• proportion of SPMS eligible for S1P-modulator class
• treatment sequencing after prior DMT failures
• discontinuation rates from safety events
• payer and guideline alignment

What is the competitive landscape for siponimod (market share, pricing pressure, and switching)?

Featured snippet answer: Competitive share is determined by relative advantage on disability progression, dosing and safety monitoring, and payer access. Without current guidance and market shares, a citation-ready projection cannot be produced.

Switching dynamics that typically matter most

• oral-to-oral switching costs (low barriers)
• safety monitoring burden
• risk management protocols (e.g., first-dose cardiac monitoring)
• patient preference for dosing convenience and tolerability history

Siponimod revenue forecast: base case, bull case, and downside scenario

Featured snippet answer: A credible revenue forecast requires:

• launch year and first-commercial-quarter assumptions
• net price and discounts (US WAC vs realized price)
• forecast horizon and persistence curve
• market growth assumptions by phenotype

No launch timing, pricing inputs, or adoption curve parameters are available in this session, so a complete and accurate projection cannot be produced here.

What a forecast model would include (structure, not numbers)

• TAM by phenotype and treated share
• penetration ramp (months 0-36)
• persistence and discontinuation
• pricing (gross to net conversion, rebates)
• competitive erosion and class effects

Key Takeaways

• Siponimod’s commercial upside hinges on label scope and real-world tolerability in the S1P class competitive environment.
• A high-quality clinical and market update requires up-to-date trial registry status, regulatory milestones, and a patent/exclusivity map tied to jurisdiction.
• This session does not contain the underlying trial, Orange Book/patent, regulatory, pricing, or market-share data required to generate an accurate clinical update and revenue projection.

FAQs

1. What is siponimod’s mechanism of action and how does it compare to other S1P modulators in MS?
2. What clinical endpoints are most important for siponimod in secondary progressive multiple sclerosis?
3. What are the safety monitoring requirements for siponimod initiation in clinical practice?
4. How do patent term adjustments and supplementary protection certificates affect siponimod generic timelines in the EU and US?
5. What competitive factors most influence adoption of a new oral DMT for SPMS?

References

No sources are cited because none were provided in this session.